Table 1 Clinical characteristics of patients with myelodysplastic syndromes.

Clinical characters	Total (n = 649)	%/range	Clinical characters	Total (n = 649)	%/range
Sex			MDS-related genes	94	14.5
Female	240	37.0	MDS-related cytogenetics	12	1.8
Male	409	63.0	mutated TP53	37	5.7
Age (years)^*	66.6	18.4–94.5	NOS	21	3.2
Laboratory data^*			2016 WHO
WBC, X 10⁹/L	3.30	0.6–32.39	MDS-5q	4	0.6
ANC, X 10⁹/L	1.50	0–23.48	MDS-SLD	95	14.6
Hb, g/dL	8.1	2.6–17.1	MDS-MLD	143	22.0
Platelet, X 10⁹/L	77	1–931	MDS-RS-SLD	45	6.9
BM blast (%)	4.4	0–19.5	MDS-RS-MLD	26	4.0
PB blast (%)	0	0–9	MDS-EB1	139	21.4
2022 ICC			MDS-EB2	190	29.3
MDS	485	74.7	MDS-U	7	1.1
del(5q)	4	0.6	Treatment
mutated SF3B1	52	8.0	HMA	156	24.0
NOS, with SLD	111	17.1	Intensive chemotherapy	20	3.1
NOS, with MLD	152	23.4	Clinical trial	27	4.2
EB	141	21.7	HSCT	103	15.9
mutated TP53	25	3.9	Supportive care only	286	44.6
MDS/AML	164	25.3	Other treatment^†	145	22.6

^*Median (range).
^†Other treatment: include low-dose cytarabine, rabbit-derived anti-thymocyte globulin, cyclosporine, danazol, eltrombopag, erythropoietin-stimulating agents, thalidomide, steroid, venetoclax-based therapy and oral chemotherapy.
ANC absolute neutrophil count, AML acute myeloid leukemia, BM bone marrow, EB excess of blasts, Hb hemoglobin, HMA hypomethylating agent, HSCT hematopoietic stem cell transplantation, ICC International Consensus Classification, MDS myelodysplastic syndromes, MDS-5q MDS with isolated del(5q), MDS-RS MDS with ring sideroblasts, MDS-EB MDS with excess blasts, MDS-SLD MDS with single lineage dysplasia, MDS-MLD MDS with multilineage dysplasia, MDS-RS-SLD MDS with ring sideroblasts and single lineage dysplasia, MDS-RS-MLD MDS with ring sideroblasts and multilineage dysplasia, MDS-U MDS, unclassifiable, NOS not otherwise specified, PB peripheral blood, WHO World Health Organization, WBC white blood cell count.

Search